Undifferentiated connective tissue disease medical therapy

Undifferentiated connective tissue disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Undifferentiated connective tissue disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other imaging findings
Other diagnostic studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Undifferentiated connective tissue disease medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Undifferentiated connective tissue disease medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Undifferentiated connective tissue disease medical therapy
CDC on Undifferentiated connective tissue disease medical therapy
Undifferentiated connective tissue disease medical therapy in the news
Blogs on Undifferentiated connective tissue disease medical therapy
Directions to Hospitals Treating Undifferentiated connective tissue disease
Risk calculators and risk factors for Undifferentiated connective tissue disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

Overview

The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as methotrexate in those exhibiting arthritis and dermatitis. Supportive therapy includes; avoiding cold exposure in those experiencing Raynaud's phenomenon, avoiding sun in photosensitivity, non-steroidal anti-inflammatory drugs for pain control, sunscreen used for photosensitivity, and emollients for dry skin and rash.

Medical Therapy

Routine measures

• Avoiding cold exposure in those experiencing Raynaud's phenomenon
• Avoiding sun in photosensitivity

Supportive therapy

• Non-steroidal anti-inflammatory drugs for pain control
• Sunscreen used for photosensitivity
• Emollients for dry skin, rash

Arthritis and dermatitis

• Oral regimen
  • Preferred regimen (1): Methotrexate 7.5 mg PO q24h for 6 months (not used for CNS symptoms or serositis)
    • Dose can be gradually increased to 13.6 mg after 6 months